| Gene symbol | MME | Synonyms | CALLA, CD10, CMT2T, NEP, SCA43, SFE | Type of gene | protein-coding |
| Chromosome | 3 | Map location | 3q25.2 | dbXrefs | |
| Description | membrane metalloendopeptidase | ||||
| Gene symbol | MS4A1 | Synonyms | B1, Bp35, CD20, CVID5, FMC7, LEU-16, S7 | Type of gene | protein-coding |
| Chromosome | 11 | Map location | 11q12.2 | dbXrefs | |
| Description | membrane spanning 4-domains A1 | ||||
| Gene symbol | CD22 | Synonyms | SIGLEC-2, SIGLEC2 | Type of gene | protein-coding |
| Chromosome | 19 | Map location | 19q13.12 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | CD22 molecule | ||||
| GTO ID | GTC1855 |
| Trial ID | NCT03407859 |
| Disease | B-Cell Acute Lymphoblastic Leukemia |
| Altered gene | CD20|CD22|CD10 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CD10/CD20/CD22 CAR-T cells |
| Phase | Early_Phase1 |
| Recruitment status | Unknown |
| Title | Sequential Treatment With CD20/CD22/CD10-CART After CD19-CART Treatment Base on MRD in Relapsed/Refractory B-ALL |
| Year | 2016 |
| Country | China |
| Company sponsor | Zhujiang Hospital |
| Other ID(s) | 2016-XYNK-002 |
| Cohort 1 | |||||||||
|
|||||||||